Non-interventional Study to Collect Real-world Clinical and Patient-reported Outcomes in Ovarian Cancer
← catalyst calendarNCT04830709 · readout in 2,416 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With North-Eastern German Society of Gynecological Oncology e.V. (NOGGO e.V.).
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
752actual
Sites
89
Country
Germany
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-06-15 | actual | When the study began enrolling |
| Primary completion | 2033-03-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2033-03-31 | estimated | The whole study's end, after follow-up |
| First posted | 2021-04-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Ovarian Cancer
Primary outcome
what the primary-completion date above is the date OFprogression-free survival (PFS)
measured date of 1st dose of 1L platinum-based CTX to disease progression (investigator-assessed according to clinical routine) or death of any cause, whichever came first, assessed up to 84 months
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed